On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.

On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.